NAS:CARA (USA) Also Trade In: Germany UK

Cara Therapeutics Inc $ 28.51 0.2 (0.71%)

Volume:
630,644
Avg Vol (1m):
1,085,070
Market Cap $:
1.42 Bil
Enterprise Value $:
1.25 Bil
PE Ratio:
158.39
PB Ratio:
5.71
Warning! GuruFocus has detected 1 Severe warning sign with CARA. Click here to check it out.
5D 3M YTD 1Y 5Y 10Y All 10Y (-%)
PE Ratio P/S Ratio P/B Ratio Price-FCF Ratio Market Cap
Current and historical daily P/E ratio for Cara Therapeutics Inc () from 2014 to Apr 17 2021. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The P/E ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the P/E ratio is positive. Also for stocks with the same P/E ratio, the one with faster growth business is more attractive. Cara Therapeutics stock (CARA) PE ratio as of Apr 17 2021 is 158.39. More Details

Cara Therapeutics PE Ratio (TTM) Chart

EMBED

Cara Therapeutics PE Ratio (TTM) Historical Data

Total 1210
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 14
Cara Therapeutics PE Ratio (TTM) Historical Data
Date PE Ratio (TTM) Data Date PE Ratio (TTM) Data
2021-04-18158.4 2021-02-15110.4
2021-04-16158.4 2021-02-12110.4
2021-04-15157.3 2021-02-11110.6
2021-04-14158.4 2021-02-10120.1
2021-04-13152.7 2021-02-09112.7
2021-04-12157.6 2021-02-08108.1
2021-04-09162.2 2021-02-05106.1
2021-04-08152.6 2021-02-04107.4
2021-04-07147.4 2021-02-03110.2
2021-04-06150.8 2021-02-02104.4
2021-04-05132.3 2021-02-01103.8
2021-04-02120.8 2021-01-29103.9
2021-04-01120.8 2021-01-28102.7
2021-03-31120.6 2021-01-27103.1
2021-03-30114.4 2021-01-26106.6
2021-03-29111.1 2021-01-25109.2
2021-03-26111.8 2021-01-22106.4
2021-03-25108.7 2021-01-21105.4
2021-03-24108.0 2021-01-20112.6
2021-03-23110.6 2021-01-19111.5
2021-03-22109.8 2021-01-15103.1
2021-03-19109.1 2021-01-14100.3
2021-03-18106.2 2021-01-1397.1
2021-03-17108.6 2021-01-1295.0
2021-03-16110.2 2021-01-1191.2
2021-03-15105.1 2021-01-0888.9
2021-03-12107.2 2021-01-0789.4
2021-03-11108.1 2021-01-0686.7
2021-03-10103.7 2021-01-0584.2
2021-03-09103.6 2021-01-0483.7
2021-03-08100.6 2020-12-3184.1
2021-03-05100.5 2020-12-3085.4
2021-03-04100.4 2020-12-2984.9
2021-03-03105.2 2020-12-2887.2
2021-03-02105.0 2020-12-240.0
2021-03-01105.1 2020-12-230.0
2021-02-26101.9 2020-12-220.0
2021-02-25107.0 2020-12-210.0
2021-02-24110.1 2020-12-180.0
2021-02-23109.4 2020-12-170.0
2021-02-22111.8 2020-12-160.0
2021-02-19111.3 2020-12-150.0
2021-02-18110.6 2020-12-140.0
2021-02-17117.1 2020-12-110.0
2021-02-16117.1 2020-12-100.0

Cara Therapeutics PE Ratio (TTM) Comparison

Company Market Cap(Mil) PE Ratio (TTM)

Business Description

Business Description

Industry
Healthcare » Biotechnology » NAICS : 325412 NAICS : 2834
Traded in other countries
Address
107 Elm Street, 9th Floor, 4 Stamford Plaza, Stamford, CT, USA, 06902
Cara Therapeutics Inc is an emerging biotechnology company involved in the development of novel therapeutics to treat human diseases associated with inflammation, pain, and pruritus. Cara's most advanced compound, CR845, aims to treat acute pain and pruritus. This patented compound has analgesic, anti-inflammatory, and antipruritic properties that can be used for multiple therapeutic applications. Additionally, Cara's objective is to use its proprietary drug-screening technology to develop a future pipeline of first-in-class molecules with analgesic and anti-inflammatory features.